Orchestra BioMed to Participate in the Piper Sandler 36th Annual Healthcare Conference
Orchestra BioMed Holdings (Nasdaq: OBIO) announced its participation in the Piper Sandler 36th Annual Healthcare Conference in New York, NY from December 3-5, 2024. The company's management will deliver a fireside chat presentation on Wednesday, December 4, 2024, at 3:00 PM EST. The presentation will be available via webcast, with a replay accessible on the Orchestra BioMed website's Events section for 90 days afterward. The company will also be available for one-on-one meetings during the conference.
Orchestra BioMed Holdings (Nasdaq: OBIO) ha annunciato la sua partecipazione alla 36ª Conferenza Annuale sulla Salute di Piper Sandler, che si terrà a New York, NY, dal 3 al 5 dicembre 2024. La direzione dell'azienda presenterà una discussione informale mercoledì 4 dicembre 2024, alle 15:00 EST. La presentazione sarà disponibile tramite webcast, con una registrazione accessibile nella sezione Eventi del sito web di Orchestra BioMed per 90 giorni dopo. L'azienda sarà inoltre disponibile per incontri individuali durante la conferenza.
Orchestra BioMed Holdings (Nasdaq: OBIO) anunció su participación en la 36ª Conferencia Anual de Salud de Piper Sandler en Nueva York, NY, del 3 al 5 de diciembre de 2024. La dirección de la empresa presentará una charla informal el miércoles 4 de diciembre de 2024, a las 3:00 PM EST. La presentación estará disponible a través de webcast, con una repetición accesible en la sección de Eventos del sitio web de Orchestra BioMed durante 90 días después. La empresa también estará disponible para reuniones individuales durante la conferencia.
Orchestra BioMed Holdings (Nasdaq: OBIO)는 2024년 12월 3일부터 5일까지 뉴욕에서 열리는 Piper Sandler 제36회 연례 헬스케어 회의에 참가한다고 발표했습니다. 회사 경영진은 2024년 12월 4일 수요일 오후 3시 EST에 화상 대화 형식의 발표를 진행할 예정입니다. 이 발표는 웹캐스트를 통해 제공되며, Orchestra BioMed 웹사이트의 이벤트 섹션에서 이후 90일 동안 재생할 수 있습니다. 회사는 또한 회의 동안 1:1 미팅도 가능할 것입니다.
Orchestra BioMed Holdings (Nasdaq: OBIO) a annoncé sa participation à la 36e Conférence Annuelle sur la Santé de Piper Sandler, qui se tiendra à New York, NY, du 3 au 5 décembre 2024. La direction de l'entreprise présentera une discussion informelle le mercredi 4 décembre 2024, à 15h00 EST. La présentation sera disponible via un webcast, avec une rediffusion accessible pendant 90 jours dans la section Événements du site web d'Orchestra BioMed. L'entreprise sera également disponible pour des réunions individuelles pendant la conférence.
Orchestra BioMed Holdings (Nasdaq: OBIO) gab seine Teilnahme an der 36. jährlichen Gesundheitskonferenz von Piper Sandler in New York, NY, vom 3. bis 5. Dezember 2024 bekannt. Das Management des Unternehmens wird am Mittwoch, dem 4. Dezember 2024, um 15:00 Uhr EST eine informelle Gesprächsrunde halten. Die Präsentation wird über einen Webcast verfügbar sein, mit einer Wiederholung, die für 90 Tage im Bereich Veranstaltungen der Orchestra BioMed-Website zugänglich ist. Das Unternehmen wird auch für Einzelgespräche während der Konferenz zur Verfügung stehen.
- None.
- None.
NEW HOPE, Pa., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that company management will present and be available for one-on-one meetings at the Piper Sandler 36th Annual Healthcare Conference being held in New York, NY from December 3-5, 2024.
Details of the presentation are shown below.
Format: Fireside Chat
Date: Wednesday, December 4, 2024
Time: 3:00 PM EST
Webcast: https://event.webcasts.com/starthere.jsp?ei=1700018&tp_key=660c0503d6
A replay of the webcast will be available on the Events section of the Orchestra BioMed website for 90 days following the presentation.
About Orchestra BioMed
Orchestra BioMed (Nasdaq: OBIO) is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships with leading medical device companies. Orchestra BioMed’s partnership-enabled business model focuses on forging strategic collaborations with leading medical device companies to drive successful global commercialization of products it develops. Orchestra BioMed’s lead product candidate is atrioventricular interval modulation (AVIM) therapy (also known as BackBeat Cardiac Neuromodulation Therapy (CNT™)) for the treatment of hypertension, a significant risk factor for death worldwide. Orchestra BioMed is also developing Virtue® Sirolimus AngioInfusion™ Balloon (SAB) for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. Orchestra BioMed has a strategic collaboration with Medtronic, one of the largest medical device companies in the world, for development and commercialization of AVIM therapy for the treatment of hypertension in pacemaker-indicated patients, and a strategic partnership with Terumo, a global leader in medical technology, for development and commercialization of Virtue SAB for the treatment of artery disease. For further information about Orchestra BioMed, please visit www.orchestrabiomed.com, and follow us on LinkedIn.
References to Websites and Social Media Platforms
References to information included on, or accessible through, websites and social media platforms do not constitute incorporation by reference of the information contained at or available through such websites or social media platforms, and you should not consider such information to be part of this press release.
Contact:
Kelsey Kirk-Ellis
Orchestra BioMed
484-682-4892
Kkirkellis@orchestrabiomed.com
FAQ
When is Orchestra BioMed (OBIO) presenting at the Piper Sandler Healthcare Conference 2024?
How long will Orchestra BioMed's (OBIO) Piper Sandler Conference webcast be available for replay?
What type of presentation will Orchestra BioMed (OBIO) give at the Piper Sandler Conference 2024?
Where is the Piper Sandler Healthcare Conference 2024 being held?
